ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Management of smoldering multiple myeloma

Management of smoldering multiple myeloma
M protein: monoclonal protein; CRAB: hypercalcemia, renal insufficiency, anemia, or bone lesions; FLC: free light chain; MRI: magnetic resonance imaging; SMM: smoldering multiple myeloma; CT: computed tomography; MM: multiple myeloma; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; CBC: complete blood count.
* CRAB criteria refers to end-organ damage (hypercalcemia, kidney impairment, anemia, or bone lesions) felt to be related to the underlying plasma cell proliferative disorder. To evaluate for bone lesions, whole body low dose CT is the preferred initial test. One or more osteolytic lesions ≥5 mm in size on CT is diagnostic of MM. Involved/uninvolved FLC ratio of 100 or more is also diagnostic of MM provided the absolute involved FLC level is at least 100 mg/L. Bone marrow plasma cells ≥60% is also diagnostic of MM.
¶ We follow these patients with clinical examination and laboratory testing (SPEP, UPEP, urine immunofixation, CBC, creatinine, calcium, and FLC ratio) after two to three months. If stable, we repeat these studies every 4 to 6 months for one year, then every 6 to 12 months. Follow-up imaging is performed every year if no abnormality was seen on prior imaging studies, and every six months if one focal lesion was seen on prior MRI.
Graphic 126135 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟